KIR3DL2 and primary cutaneous T-cell non-Hodgkin lymphoma: In addition, preliminary clinical studies of a novel targeted immunotherapy for cutaneous T-cell lymphomas using the anti-KIR3DL2 mAb IPH4102 are now underway.